AGENDA AT GLANCE
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
👤 Felicia Pradera, Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna, Australia
Navigating the Evolving RNA Therapeutic Landscape in Asia:
Regulatory Challenges, Strategic Partnerships, and Emerging Opportunities
9:00
Leadership Panel Discussion: Assessing the Current RNA Therapeutics Landscape: Challenges and Opportunities
- Exploring recent breakthroughs in RNA drug development, including mRNA vaccines, RNA interference, and gene editing techniques
- Reviewing the current regulatory framework for RNA-based therapeutics and the challenges faced in obtaining approvals for new RNA therapies
- Examining the hurdles in the large-scale production and distribution of RNA therapeutics, and the solutions being explored to overcome these barriers
- Discussing how RNA therapeutics can be tailored for personalized treatments, and their potential in revolutionizing healthcare through targeted therapies for genetic disorders, cancer, and more
- Cross-border collaboration in addressing emerging diseases
Moderator:
👤 Andreas Donny Prakasa, Head of Corporate Relationship, PT Etana Biotechnologies, Indonesia
Panelists:
👤 Felicia Pradera, Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna, Australia
👤 Vaibhav Dubey, Senior General Manager, Kashiv BioSciences, India
👤 Volker Patzel, Assistant Professor, National University of Singapore, Singapore
9:45
Advancing RNA Therapeutics: Southeast Asia’s Emerging Landscape and Australia’s Strategic Role
- Southeast Asia is emerging as a hub for RNA therapeutics, with Thailand and Singapore leading develpoment and GMP manufacturing through organisations like SCG Cell Therapy and A*STAR
- Technological advances in RNA synthesis, purification and scalable production are enabling broader adoption of RNA-based treatments and personalised medicine
- Australia is a key contributor to RNA innovation, supported by national initiaves such as RNA Blueprint and Medical Science Co-investment Plan, which foster research, regulation and global collaboration
👤 Helen Oh, Regional Co-Lead for Critical Tech and Health, Australian Trade and Investment Commission, Singapore
10:10
Strengthening mRNA vaccine development capacity in Malaysia
- Malaysia’s national vaccine agenda: Coordinated initiatives and multi-stakeholder efforts to achieve self-reliance
- Upstream mRNA development for neglected diseases: Current progress, challenges and capability gaps
- Strategies to strengthen R&D, bioprocessing, preclinical and manufacturing for sustainable vaccine development
👤 Natasha Lee Hai Yen, Senior Lecturer, Universiti Malaya, Malaysia
10:35
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Optimizing RNA Synthesis for Scalable Therapeutic Production
11:05
Minimalistic non-viral DNA vectors expressing computationally designed functional RNA for gene therapy, mitochondrial gene therapy, and genetic vaccination
- Design and manufacture of minimalistic, dumbbell-shaped, non-viral DNA delivery vectors
- Computational design of functional RNA
- Application of non-viral vectors for gene therapy and genetic vaccination
👤 Volker Patzel, Assistant Professor, National University of Singapore, Singapore
11:30
Formulation and Process Development Strategies for Scalable mRNA Therapeutics
👤 Vaibhav Dubey, Senior General Manager, Kashiv BioSciences, India
11:55
Establishing Asia’s First mRNA Vaccine Manufacturing Ecosystem: Lessons from Technology Transfer & Scale-Up
- Strategic Vision: Building on strong partnerships and a unique market position, PT Etana is driving regional expansion through the world’s first Halal-certified mRNA vaccine, a major differentiator shaping a sustainable future in biopharmaceutical innovation.
- Technical Excellence: Achieved functional mRNA vaccine development, including pre-clinical trials, within just two months, demonstrating exceptional speed and technical capability to accelerate access to life-saving biopharmaceuticals in Indonesia.
- Public–Private Collaboration: Empowered by close collaboration with the Indonesian Ministry of Health, PT Etana is fostering a robust biotechnology ecosystem that strengthens national resilience and advances high-technology biologics innovation.
👤 Andreas Donny Prakasa, Head of Corporate Relationship, PT Etana Biotechnologies, Indonesia
12:25
Lunch, Exhibition Viewing & 1-1 Attendees Networking
RNA Mechanisms and Modulation: From Cellular Regulation to Synthetic Applications
1:30
Advancing Kidney-Targeted siRNA Therapies: Precision Delivery and NHP Proof-of-Concept
👤 Ryan Huang Yuanyu, Founder, Chairman & Chief Scientist Officer, Rigerna Therapeutics, China
1:45
Key CMC Considerations for mRNA Therapeutics towards IND Approval
- Deciphering the end-to-end process for mRNA therapeutics
- Emphasizing the key CMC consideration points for mRNA therapeutics
- Introduction to CATUG Biotechnology's one-stop CMC service
👤 Piao Xijun, Vice President of Technology, CATUG Biotechnology, China
2:10
Logic‑Gated mRNA: Programmable RNA Sensors for Precision Therapeutics
👤 Sophia Lugo, CEO & Chairman, Radar Therapeutics, USA
2:35
MicroRNAs and Gene Expression in Cognitive Health and Chronic Disease: Epigenetic Insights from Lifestyle and Intergenerational Studies
- Role of physical activity in modulating miRNA expression linked to cognitive function and chronic disease outcomes
- Mechanisms by which specific microRNAs regulate gene expression in lifestyle-related disorders
- Epigenetic and intergenerational impacts of miRNA expression patterns in long-term disease risk and healthspan
👤 Vimolmas Tansathitaya, Assistant Professor, Mahidol University, Thailand
3:05
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Case Study & Insights from Asia in Scaling RNA-Based Therapies
3:35
Driving Growth in RNA Therapeutics: Policy and Strategic Collaborations in Australia
- How Melbourne and Australia built an end-to-end mRNA value chain
- Investing in R&D, development and manufacturing
- Strategic partnerships, growing international collaborations
- Working together to develop new vaccines for pathogens of concern to the APAC region
👤 Rebecca Skinner, Director, Research and Industry Development, mRNA Victoria, Australia
4:00
RNAi-Based Approaches in Aquaculture: Advancing RNA Technologies Beyond Human Therapeutics
- Transforming Aquaculture Health: Pioneering bio- and nano-encapsulated antiviral dsRNA to replace antibiotics and boost shrimp resilience against deadly viruses
- From Lab to Farm: Scalable, pathogen-specific RNAi solutions that significantly improve survival rates and are ready for commercial deployment
- Green by Design: Fully degradable, residue-free technology that protects both animal health and the environment
👤 Vanvimon Saksmerprome, Principal Researcher, National Center for Genetic Engineering and Biotechnology, Thailand
4:25
C-Suite Think Tank: Unlocking the Next Wave of mRNA-Based Vaccines, Therapeutics & Platforms in Asia: Advancing mRNA Drugs Towards Clinical Reality
This is your chance to hear from pioneering leaders in the mRNA space across Asia, who will share their insights on the ambitions, strategies, and challenges in advancing mRNA technology. The discussion will focus on identifying unmet needs, promising indications, and the development of the next generation of mRNA medicines.
Key Discussion Points:
- What are the emerging opportunities, promising targets, and applications for mRNA technology in Asia that could drive clinical success?
- What are the biggest challenges in balancing scientific innovation with strategic pipeline management as we approach 2026?
- How can mRNA companies in Asia reduce risks, extend cash flow, and position themselves to become attractive, investable SMEs?
- What lessons can be learned from Asia's rapidly evolving mRNA landscape to foster growth and global impact in this sector?
Moderator:
👤 Petro Terblanche, CEO, Afrigen Biologics & Vaccines, South Africa
Panelists:
👤 Zeng Xian, CEO & Co-Founder, Byterna Therapeutics, China
👤 Ying Bo, CEO, Abogen Biosciences, China
👤 Wonil Kim, Chief Scientific Officer (CSO), Aston Sci., S.Korea
5:15
Chairman Closing Remarks
5:20
End of Day 1 Conference & Networking Cocktail
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
👤 Wonil Kim, Chief Scientific Officer (CSO), Aston Sci., S.Korea
Novel RNA Modalities and Indications: Advancements, Challenges, and Recent Breakthroughs
9:00
AI-Driven In Silico Epitope Screening for mRNA-Based Cancer Vaccine Development
- Th-Vac® is an AI-powered system designed to help create mRNA cancer vaccines that activate CD4+ helper T cells
- mRNA cancer vaccines can specifically target cancer-associated antigens such as TROP2, PD-L1, IDO, and KRAS
- Th-Vac® aims to address current challenges in cancer immunotherapy and enhance future treatment options
👤 Wonil Kim, Chief Scientific Officer (CSO), Aston Sci., S.Korea
9:25
Next-Gen Polymer/Lipid Based Delivery Systems for RNA Therapeutics
- ACM Tunable Platform (ATP): PEG-lipid alternative polymersome delivery system enabling targeted RNA delivery with liquid stability at 2–8 °C, maintaining immunogenicity comparable to LNP-mRNA vaccines.
- Clinical Validation: Phase 1 COVID-19 vaccine trial demonstrated robust safety and superior thermostability of the block copolymer platform, establishing readiness for broad RNA applications.
- Pipeline Expansion: Advancing next-gen mRNA vaccines, therapeutic RNA programs and targeted RNA delivery to immune cells.
- Strategic Advantage: Combines payload flexibility, precision immune targeting and real-world deployability—a differentiated alternative to LNPs for RNA vaccines and therapeutics.
👤 Madhavan Nallani, Founder & CEO, ACM Biolabs, Singapore
9:50
Advancing cmRNA Therapeutics: Innovations in In Vivo CAR‑T Cell Therapy
- Innovations in cmRNA technology and their potential in nest-generation mRNA therapeutics
- CellectLNP Platform for efficient extra-hepatic and T-cell targeted delivery of cmRNA for in vivo cell engineering
- Robust B-cell depletion of cmRNA-based in vivo CAR-T supports its promising future in autoimmune diseases treatment
👤 Zeng Xian, CEO & Co-Founder, Byterna Therapeutics, China
10:15
Innovative Delivery Platforms for siRNA Therapeutics
- Proprietary Delivery Tech: PNP and GalNAc platforms enabling precise siRNA targeting for cancer, fibrosis, and more.
- Clinical Highlights: STP705 (Phase IIb/III) and STP122G (Phase I) showing strong efficacy and safety data.
- Next-Gen Innovations: Expanding to CNS, lung, and gut with novel approaches like AODC for broader RNAi therapy.
👤 Poon Hung Fai, CEO, Sirnaomics, China
10:40
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
RNA Delivery: Innovative Mechanisms and Therapeutic Applications
11:15
Delivery of mRNA for Vaccines, Cancer and Autoimmune Diseases
- Introduction of Abogen's RNA technology platform
- Next-Gen LNP for safe and effective delivery of mRNA in mice and NHP
- Clinical updates of Abogen's research in vaccines, cancer and autoimmune diseases
👤 Ying Bo, CEO, Abogen Biosciences, China
11:40
Designing and Optimising RNA Delivery Platforms for Targeted Therapeutic Applications
- The critical role of designing delivery platforms in RNA Therapeutics to align with desired immune outcomes
- Directing RNA carriers to specific immune cells to help fine-tune immune responses across various disease settings.
- Incorporating immune insights into RNA and delivery design to support the advancement of more refined RNA therapies.
👤 Aprilia Paramitasari, Medical Doctor, Taipei Medical University, Taiwan
12:05
Panel Discussion: Advancing RNA Delivery Systems: Enhancing Efficiency and Precision
- Overview of current RNA delivery technologies and their limitations.
- Emerging innovations in lipid nanoparticles (LNP) and alternative delivery systems.
- Strategies for improving tissue targeting and minimizing off-target effects.
- Regulatory challenges and considerations for novel RNA delivery systems.
Moderator:
👤 Aprilia Paramitasari, Medical Doctor, Taipei Medical University, Taiwan
Panelists:
👤 Ryan Huang Yuanyu, Founder, Chairman & Chief Scientist Officer, Rigerna Therapeutics, China
👤 Poon Hung Fai, CEO, Sirnaomics, China
👤 Madhavan Nallani, Founder & CEO, ACM Biolabs, Singapore
12:35
Lunch, Exhibition Viewing & 1-1 Attendees Networking
Next-Gen RNA Platforms: Enabling Innovation in Therapeutics and Manufacturing
1:50
👤 Reserved for Fadinda Shafira, AI Engineer, PT Kalbe Farma, Indonesia
2:15
Translating siRNA and Gene Therapy Innovation into Clinical Success
- Overview of current SiRNA market in worldwide and China
- Advances and strategic directions in siRNA drug discovery and development
- Key technological advantages and future opportunities in RNA-based therapeutics
👤 Adam Zhao Chunlin, CEO & Chairman, Anlong Bio, China
2:40
Harnessing Antiviral siRNA Therapeutics and Lipid Nanoparticle Delivery for Acute and Chronic Viral Infections
- RNAi pathways: Transcriptional silencing of the promoter or post-transcriptional mRNA degradation
- Safety of lipid nanoparticles for respiratory delivery
- Respiratory devices for delivery of RNAi therapeutics
👤 Chantelle Ahlenstiel, Senior Research Fellow, Kirby Institute, UNSW, Australia
3:05
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Future Directions in RNA Therapeutics: Trends and Innovations
3:35
Advancing Regional RNA Innovation through Strategic Collaboration and Research Translation
👤 Felicia Pradera, Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna, Australia
4:00
Public Health Preparedness with mRNA and Viral Vectors: Building Capabilities at the National Level
👤 Indra Rudiansyah, Project Leader for mRNA and Viral Vector Vaccines Programme, PT Bio Farma, Indonesia
4:25
Clinical Development Strategies for RNA-Based Vaccines: From Candidate Selection to Regulatory Readiness
- Adaptive and Accelerated Trial Designs
- Endpoint Selection and Immunogenicity Assessment
- Safety Monitoring and Risk Mitigation
👤 Subhash Thuluva, Senior VP & Head-Clinical Development, Biological E. Limited, India
4:50
Panel Discussion: Next-Generation RNA Therapeutics & Diagnostics: Advancements, Platforms, and Fast-Tracked Applications
- Overview of emerging RNA technologies and scientific platforms, including RNA editing, self-amplifying RNA, and synthetic biology
- How RNA biology is evolving to support more precise and effective RNA-based therapeutics and diagnostics
- Key RNA approaches and therapeutic indications (small and long RNAs) currently fast-tracked for clinical use, with a focus on cancer, genetic disorders, and infectious diseases
- What steps are being taken to scale RNA therapies and diagnostics, from technology development to clinical adoption, including regulatory challenges and manufacturing innovations
Moderator:
👤 Subhash Thuluva, Senior VP & Head-Clinical Development, Biological E. Limited, India
Panelists:
👤 Adam Zhao Chunlin, CEO & Chairman, Anlong Bio, China
👤 Indra Rudiansyah, Project Leader for mRNA and Viral Vector Vaccines Programme, PT Bio Farma, Indonesia
👤 Chantelle Ahlenstiel, Senior Research Fellow, Kirby Institute, UNSW, Australia
5:20
Chairman Closing Remarks
5:25
End of Day 2 conference
For Speaking Opportunities, Kindly Contact:
Lara Santiago
Senior Portfolio Specialist
[email protected] | +63 91762 10686
Share With Your Network
